Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.12
+2.681.87%
Post-market: 146.120.00000.00%19:56 EDT
Volume:5.38M
Turnover:787.47M
Market Cap:181.29B
PE:-55.88
High:147.91
Open:144.52
Low:143.50
Close:143.44
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.00
T/O Rate:0.43%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.33
PE(LYR):21.55

Loading ...

OverviewCompanyNewsFilings

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Jun 26

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

TIPRANKS
·
Jun 25

Dow Jones Top Company Headlines at 3 am ET: Anthropic Claims Alibaba Ran 'brazen' Campaign to Access Its Claude AI Model | Micron ...

Dow Jones
·
Jun 25

Gsk's HIV Franchise Seems Underappreciated

Dow Jones
·
Jun 25

Dow Jones Top Company Headlines at 5 PM ET: Micron Shares Jump as Chip Shortage Projected to Last Beyond 2027 | New ...

Dow Jones
·
Jun 25

FDA Approves Gilead Trodelvy for First-line Metastatic Triple-negative Breast Cancer Treatment

Reuters
·
Jun 25

New Drugs are Replacing Chemo for Aggressive Breast Cancer

Dow Jones
·
Jun 25

Gilead Sciences Shares Gain Ground with Relatively Light Volume, Last up 1.2% at $126.59

THOMSON REUTERS
·
Jun 25

FDA approves Gilead’s Trodelvy for two indications

TIPRANKS
·
Jun 25

FDA Clears Sacituzumab Govitecan-hziy for Two Indications in Adults with Triple-negative Breast Cancer

Reuters
·
Jun 25

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy & in Combination with Pembrolizumab for First-line Treatment of Triple-negative Breast Cancer

THOMSON REUTERS
·
Jun 25

FOCUS-US provides Ebola treatment for outbreak in Congo, bringing trials closer

Reuters
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD)

TIPRANKS
·
Jun 24

Gilead announces EC grants marketing authorization for Trodelvy

TIPRANKS
·
Jun 23

Alpha Cognition elects Robert Wills as board chairman

Reuters
·
Jun 23

Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment

MT Newswires Live
·
Jun 23

EU approves Gilead Trodelvy as first-line treatment for metastatic triple-negative breast cancer patients ineligible for PD-(L)1 inhibitors

Reuters
·
Jun 23

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for Pd-(L)1 Inhibitors

THOMSON REUTERS
·
Jun 23

Moderna Inc. Stock Sheds 7.2%, Underperforms Peers

Dow Jones
·
Jun 23

Gilead Sciences Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 19